Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by AMoschittoon Aug 05, 2021 10:00am
96 Views
Post# 33654171

RE:RE:RE:RE:Summary of Expectations Request Please

RE:RE:RE:RE:Summary of Expectations Request Please

Connected to this thread, i know JFM said we would be close to double the docetaxel MTD this next week according to his best estimates... I'm curious what we expect the company to communicate about the MTD? Will they use this as a chance to share multiple points of good news from now to Q4 data and safety results. Or will they wait all the way until we have all that info and do it all at once? 

Is it normal for a company to update the market on an MTD prior to the safety and data efficacy? 

PL has said we will update everyone as soon as we can and as we hit milestones. Establishing an MTD is a milestone we would love to hear and I wouldn't think relies on the safety/efficacy data being totally ferreted out to release the data responsibly. I could be wrong tho. 

<< Previous
Bullboard Posts
Next >>